ArticleCancer reports (Hoboken, N.J.)2026
Downregulation of TNFAIP3 Associated With Poor Prognosis and Immune Response in Breast Cancer.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Downregulation of TNFAIP3 Associated With Poor Prognosis and Immune Response in Breast Cancer.Cancer reports (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundBreast cancer (BRCA) progression is closely linked to dysregulated inflammatory processes within the tumor microenvironment (TME). TNFAIP3, a key regulator of TNF-α signaling, plays a dual role in cancer biology, but its precise function in BRCA pathogenesis and immune modulation remains unclear.
aimsThis study aimed to elucidate the clinical significance, immune regulatory role, and molecular mechanisms of TNFAIP3 in BRCA progression. METHODS AND
resultsWe conducted an analysis of RNA-seq data from 1113 BRCA samples and 113 normal samples sourced from TCGA, along with protein data from 125 BRCA samples and 18 normal samples obtained from the CPTAC database. Comprehensive analyses included: (1) differential expression across cancer types and BRCA subtypes; (2) correlation with clinicopathological features; (3) survival analysis using Kaplan-Meier and Cox regression; (4) immune cell infiltration assessment via ssGSEA; and (5) co-expression analysis of TNFAIP3-LINC01096. TNFAIP3 was significantly downregulated in BRCA (p < 0.001) and associated with aggressive features, including advanced TNM stage (T4 vs. T1, p = 0.021) and poor prognosis (HR = 1.48, p = 0.035). Immune profiling revealed strong correlations with cytotoxic T cells (ρ = 0.632) and dendritic cells (ρ = 0.602). A novel TNFAIP3-LINC01096 regulatory network was identified (ρ = 0.582, p < 0.001), potentially mediated by shared miR-3130-3p binding sites.
conclusionOur findings suggest a role of TNFAIP3 as a critical regulator of BRCA progression and tumor immunity. The TNFAIP3-LINC01096 axis represents a promising therapeutic target, particularly for immunotherapy-resistant cases. These results provide a rationale for developing TNFAIP3-based prognostic tools and immunomodulatory strategies in BRCA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.